Found: 21
Select item for more details and to access through your institution.
Non-Invasive Local Acoustic Therapy Ameliorates Diabetic Heart Fibrosis by Suppressing ACE-Mediated Oxidative Stress and Inflammation in Cardiac Fibroblasts.
- Published in:
- Cardiovascular Drugs & Therapy, 2022, v. 36, n. 3, p. 413, doi. 10.1007/s10557-021-07297-6
- By:
- Publication type:
- Article
CD36+/CD61+ Microparticles Correlate with the Risk of Percutaneous Cardiac Interventions in Coronary Artery Disease Patients and the Effects of Ticagrelor.
- Published in:
- Cardiovascular Drugs & Therapy, 2022, v. 36, n. 3, p. 455, doi. 10.1007/s10557-021-07184-0
- By:
- Publication type:
- Article
SLC7A11/xCT Prevents Cardiac Hypertrophy by Inhibiting Ferroptosis.
- Published in:
- Cardiovascular Drugs & Therapy, 2022, v. 36, n. 3, p. 437, doi. 10.1007/s10557-021-07220-z
- By:
- Publication type:
- Article
Evaluating a Simple Approach to Identify Adults Meeting the 2018 AHA/ACC Cholesterol Guideline Definition of Very High Risk for Atherosclerotic Cardiovascular Disease.
- Published in:
- Cardiovascular Drugs & Therapy, 2022, v. 36, n. 3, p. 475, doi. 10.1007/s10557-021-07167-1
- By:
- Publication type:
- Article
Efficacy and Safety of the Fixed-Dose Versus Variable-Dose of 4-PCC for Vitamin K Antagonist Reversal: A Comprehensive Systematic Review and Meta-Analysis.
- Published in:
- Cardiovascular Drugs & Therapy, 2022, v. 36, n. 3, p. 533, doi. 10.1007/s10557-021-07192-0
- By:
- Publication type:
- Article
Protective Role of lncRNA TTN-AS1 in Sepsis-Induced Myocardial Injury Via miR-29a/E2F2 Axis.
- Published in:
- Cardiovascular Drugs & Therapy, 2022, v. 36, n. 3, p. 399, doi. 10.1007/s10557-021-07244-5
- By:
- Publication type:
- Article
Association of Antihypertensive Agents with the Risk of In-Hospital Death in Patients with Covid-19.
- Published in:
- Cardiovascular Drugs & Therapy, 2022, v. 36, n. 3, p. 483, doi. 10.1007/s10557-021-07155-5
- By:
- Publication type:
- Article
Sulforaphane Does Not Protect Right Ventricular Systolic and Diastolic Functions in Nrf2 Knockout Pulmonary Artery Hypertension Mice.
- Published in:
- Cardiovascular Drugs & Therapy, 2022, v. 36, n. 3, p. 425, doi. 10.1007/s10557-022-07323-1
- By:
- Publication type:
- Article
Response to the Letter on "The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus".
- Published in:
- 2022
- By:
- Publication type:
- Letter to the Editor
Letter to the Editor Regarding "The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus".
- Published in:
- Cardiovascular Drugs & Therapy, 2022, v. 36, n. 3, p. 571, doi. 10.1007/s10557-021-07301-z
- By:
- Publication type:
- Article
The Effect of Tafamidis on Circulating Endothelial Progenitor Cells in Patients with Transthyretin Cardiac Amyloidosis.
- Published in:
- Cardiovascular Drugs & Therapy, 2022, v. 36, n. 3, p. 489, doi. 10.1007/s10557-021-07265-0
- By:
- Publication type:
- Article
The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus.
- Published in:
- Cardiovascular Drugs & Therapy, 2022, v. 36, n. 3, p. 561, doi. 10.1007/s10557-021-07291-y
- By:
- Publication type:
- Article
β-Hydroxybutyrate Exacerbates Hypoxic Injury by Inhibiting HIF-1α-Dependent Glycolysis in Cardiomyocytes—Adding Fuel to the Fire?
- Published in:
- Cardiovascular Drugs & Therapy, 2022, v. 36, n. 3, p. 383, doi. 10.1007/s10557-021-07267-y
- By:
- Publication type:
- Article
Dyslipidemia, chronic kidney disease, atherosclerotic cardiovascular disease, and statins.
- Published in:
- Cardiovascular Drugs & Therapy, 2022, v. 36, n. 3, p. 569, doi. 10.1007/s10557-021-07284-x
- By:
- Publication type:
- Article
Impact of Calcium Channel Blockers on Aspirin Reactivity in Patients with Coronary Artery Disease.
- Published in:
- Cardiovascular Drugs & Therapy, 2022, v. 36, n. 3, p. 467, doi. 10.1007/s10557-021-07295-8
- By:
- Publication type:
- Article
Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Cardiovascular Outcomes in Patients with Diabetes Mellitus and Heart Failure.
- Published in:
- Cardiovascular Drugs & Therapy, 2022, v. 36, n. 3, p. 497, doi. 10.1007/s10557-021-07234-7
- By:
- Publication type:
- Article
Why Not Dipyridamole: a Review of Current Guidelines and Re-evaluation of Utility in the Modern Era.
- Published in:
- Cardiovascular Drugs & Therapy, 2022, v. 36, n. 3, p. 525, doi. 10.1007/s10557-021-07224-9
- By:
- Publication type:
- Article
Is the Endothelium the Missing Link in the Pathophysiology and Treatment of COVID-19 Complications?
- Published in:
- Cardiovascular Drugs & Therapy, 2022, v. 36, n. 3, p. 547, doi. 10.1007/s10557-021-07207-w
- By:
- Publication type:
- Article
The Association between Multi-Vessel Coronary Artery Disease and High On-Aspirin Platelet Reactivity.
- Published in:
- Cardiovascular Drugs & Therapy, 2022, v. 36, n. 3, p. 449, doi. 10.1007/s10557-021-07195-x
- By:
- Publication type:
- Article
Rationale and Design of the ADIDAS Study: Association Between Dapagliflozin-Induced Improvement and Anemia in Heart Failure Patients.
- Published in:
- Cardiovascular Drugs & Therapy, 2022, v. 36, n. 3, p. 505, doi. 10.1007/s10557-021-07176-0
- By:
- Publication type:
- Article
The Molecular Mechanisms of Cardiotoxicity Induced by HER2, VEGF, and Tyrosine Kinase Inhibitors: an Updated Review.
- Published in:
- Cardiovascular Drugs & Therapy, 2022, v. 36, n. 3, p. 511, doi. 10.1007/s10557-021-07181-3
- By:
- Publication type:
- Article